Company: BDRX
Filing Date: 2025-05-12
Form Type: 424B3
Source: 0001214659-25-007342
Chunk: 25

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-05-12
Form: 424B3
Chunk 25
---
='center'>DESCRIPTION OF SHARE CAPITAL</div>

The following describes our issued share capital, summarizes the material provisions of our Articles of Association and highlights certain differences in corporate law in the United Kingdom and the United States. This description of our share capital and summary of our Articles of Association is not complete, and is qualified by reference to our Articles of Association. You should read our Articles of Association, which are filed as an exhibit to the registration statement of which this prospectus forms a part, for the provisions that are important to you.

The following describes our issued share capital, summarizes the material provisions of our articles of association and highlights certain differences in corporate law in the United Kingdom and the United States. Please note that this summary is not intended to be exhaustive. For further information please refer to the full version of our Articles of Association, which is included as an exhibit to the registration statement of which this prospectus is part.

General

We are a public limited company
organized under the laws of England and Wales under registered number 09216368. Our registered office is 1 Caspian Point, Caspian Way,
Cardiff, CF10 4DQ, United Kingdom. The principal legislation under which we operate and our shares are issued is the Companies Act.

Our issued share capital as
of December 31, 2024 and April 1, 2025 was 6,685,918,822 Ordinary Shares and 25,617,408,922 Ordinary Shares, respectively, with each Ordinary
Share having a nominal value of £0.00005 per share. Each issued Ordinary Share is fully paid. We currently have 1,000,001 A Deferred
Shares, 4,063,321,420 B Deferred Shares, 126,547,389,518 C Deferred Shares, and no preference shares in our issued share capital.

There is no limit to the number
of Ordinary Shares or preference shares that we are authorized to issue, as the concept of authorized capital is no longer applicable
under the provisions of the Companies Act. There are no conversion rights, redemption provisions or sinking fund provisions relating to
any Ordinary Shares.

We are not permitted under
English law to hold our own Ordinary Shares unless they are repurchased by us and held in treasury. We do not currently hold any of our
own Ordinary Shares.

History of Share Capital

Since January 1, 2022, our
issued share capital has changed as provided below.

On March 22, 2022, we issued